Boston Scientific trims annual profit forecast on softer Watchman device demand

Reuters

Wed, July 29, 2026 astatine 6:16 AM CDT 2 min read

July 29 (Reuters) - Medical instrumentality shaper Boston Scientific connected Wednesday lowered its yearly nett forecast, citing unit connected its Watchman bosom ‌device business.

The company, successful May, warned of unit connected its ‌Watchman bosom device, a tiny implant utilized to assistance forestall stroke-causing humor clots successful patients ​with atrial fibrillation, owed to softer-than-expected uptake.

Boston Scientific said maturation was being weighed down by a diminution successful standalone Watchman procedures arsenic physicians progressively harvester the implant with different cardiac treatments during a azygous visit.

As a result, ‌the institution said it expects ⁠flat Watchman gross maturation successful the 2nd and apt 3rd quarter, contempt continued uptake successful combined procedures.

On Monday, Boston ⁠Scientific's committee approved a caller company-wide restructuring program aimed astatine cutting costs and amended positioning the institution for aboriginal growth.

The plan, approved connected July 21, ​includes proviso ​chain optimization, accumulation shifts betwixt manufacturing ​sites and organizational changes, and ‌is expected to beryllium mostly completed by the extremity of 2029.

Shares of the institution were up astir 4% premarket aft it bushed second-quarter results.

The Massachusetts-based institution posted second-quarter adjusted nett of 86 cents per share, supra analysts' estimation of 83 cents per share, according to LSEG data.

Its quarterly ‌revenue came successful astatine $5.44 billion, supra analysts' ​expectations of $5.36 billion.

The company's cardiovascular portion posted ​quarterly income of $3.62 billion, beating ​estimates of $3.58 billion.

Boston Scientific present expects 2026 adjusted nett ‌per stock to beryllium betwixt $3.28 and $3.32, ​compared to its ​prior presumption successful the scope of $3.34 to $3.41 per share. Analysts were expecting yearly adjusted nett astatine $3.36 per share.

The institution present expects integrated ​sales maturation for 2026 ‌to beryllium betwixt 5% and 6%, compared to its erstwhile expectations ​in the scope of 6.5% to 8%.

(Reporting by Siddhi Mahatole ​in Bengaluru; Editing by Tasim Zahid)